Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3251 to 3300 of 3807 results for treatment

  1. What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?

    are at high risk of infection, or who would find it difficult to access treatment at a later date if they screened positive for a...

    Research recommendation
    Published
    8 November 2019

  2. What clinical features and laboratory investigations can be used to better stratify risk for women in labour with signs of sepsis (including fever and tachycardia)?

    sepsis, but they agreed that if concerns are enough to warrant antibiotic treatment, more frequent observations are needed because of...

    Research recommendation
    Published
    16 August 2019

  3. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  4. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

    Medtech innovation briefing
    Published
    1 November 2022

  5. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

    Medtech innovation briefing
    Published
    15 March 2022

  7. Endoscopic sleeve gastroplasty for obesity (HTG711)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

    HealthTech guidance
    Published
    22 February 2024
    View recommendations

    Sections for HTG711

  8. NICE-wide topic prioritisation: the manual (PMG46)

    This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board

  9. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse (HTG539)

    Evidence-based recommendations on bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse in adults. This involves replacing weakened or stretched ligaments that support the uterus and hold the pelvic organs in place with mesh tape.

    HealthTech guidance
    Published
    4 March 2020
    View recommendations

    Sections for HTG539

  10. Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth (HTG500)

    Evidence-based recommendations on laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth. This involves placing a stitch around the upper part of the cervix to keep it closed.

    HealthTech guidance
    Published
    30 January 2019
    View recommendations

    Sections for HTG500

  11. Technology appraisal methods and processes used before 2022

    Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.

  12. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  13. Board, executive team and senior leaders interests register

    Outside interests of the NICE board

  14. Violent and aggressive behaviours in people with mental health problems (QS154)

    This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 June 2017
    View quality statements

    Sections for QS154

  15. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

    NICE guideline
    Published
    9 August 2017
    View recommendations

    Sections for NG72

  16. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued Reference number: GID-TAG423

    Technology appraisal guidance
    Discontinued

  17. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued

  18. Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (HTG66)

    Evidence-based recommendations on artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis. This involves removing the diseased joints and replacing them with artificial ones.

    HealthTech guidance
    Published
    23 February 2005
    View recommendations

    Sections for HTG66

  19. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  20. Curos for preventing infections when using needleless connectors (HTG510)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

    HealthTech guidance
    Published
    9 May 2019
    View recommendations

    Sections for HTG510

  21. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  22. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  23. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  24. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  25. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

    Medtech innovation briefing
    Published
    29 November 2016

  26. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

    Medtech innovation briefing
    Published
    26 August 2014

  27. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed prostate-specific antigen thresholds for people with symptoms of prostate cancer, including those at high risk of developing prostate cancer (such as those with an African family background or a family history of prostate cancer)?

    to be referred to secondary care to avoid invasive investigations and treatment that might not benefit them. Therefore, the committee...

    Research recommendation
    Published
    7 January 2022

  29. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

    Medtech innovation briefing
    Published
    28 February 2019

  30. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Withdrawn advice

  31. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury (HTG727)

    Evidence-based recommendations on phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. This involves stimulating the phrenic nerve to make the diaphragm contract, helping people to breathe without a ventilator.

    HealthTech guidance
    Published
    21 August 2024
    View recommendations

    Sections for HTG727

  32. Making a positive impact: people and communities network case studies

    Making a positive impact: NICE people and communities network case studies

  33. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  34. Making a positive impact: people and communities network case studies

    Making a positive impact: NICE people and communities network case studies

  35. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  36. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  37. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  38. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  39. Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant (HTG732)

    Evidence-based recommendations on direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. This involves inserting a metal implant through the skin and into the centre of the bone of the stump and attaching a prosthetic limb to it.

    HealthTech guidance
    Published
    17 December 2024
    View recommendations

    Sections for HTG732

  40. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  41. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

    HealthTech guidance
    Last updated
    5 August 2025
    View recommendations

    Sections for HTG728

  42. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (HTG519)

    Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. This involves inserting a piece of mesh to strengthen the abdominal wall.

    HealthTech guidance
    Published
    26 June 2019
    View recommendations

    Sections for HTG519

  43. Zio XT for detecting cardiac arrhythmias (HTG562)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

    HealthTech guidance
    Published
    1 December 2020
    View recommendations

    Sections for HTG562

  44. Thopaz+ portable digital system for managing chest drains (HTG465)

    Evidence-based recommendations on Thopaz+ for managing chest drains.

    HealthTech guidance
    Last updated
    6 June 2022
    View recommendations

    Sections for HTG465

  45. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  46. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  47. Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)

    Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.

    HealthTech guidance
    Published
    28 October 2020
    View recommendations

    Sections for HTG557

  48. Palforzia for treating peanut allergy in children and young people (TA769)

    NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.

    Withdrawn guidance

  49. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Withdrawn guidance

  50. NICE encourages further research into radiofrequency ablation for gastric antral vascular ectasia and collaborative publication of data from local audit. Patient selection should be clearly documented, including details of prior treatments. Outcomes should include success and duration of effect in controlling bleeding and the effect of this on the need for blood transfusion. All complications should be reported. NICE may update the guidance on publication of further evidence.

    Patient selection should be clearly documented, including details of prior treatments. Outcomes should include success and duration of...

    Research recommendation
    Published
    6 October 2015